Death ligands such as CD95 ligand (CD95L) or tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand (TRAIL/Apo2L) induce apoptosis in radiochemotherapy-resistant human malignant glioma cell lines. The death-signaling TRAIL receptors 2 (TRAIL-R2/death receptor (DR) 5) and TRAIL-R1/ DR4 were expressed more abundantly than the nondeath-inducing (decoy) receptors TRAIL-R3/DcR1 and TRAIL-R4/DcR2 in 12 human glioma cell lines. Four of the 12 cell lines were TRAIL/Apo2L-sensitive in the absence of a protein synthesis inhibitor, cycloheximide (CHX). Three of the 12 cell lines were still TRAIL/ Apo2L-resistant in the presence of CHX. TRAIL-R2 expression predicted sensitivity to apoptosis. Coexposure to TRAIL/Apo2L and cytotoxic drugs such as topotecan, lomustine (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, CCNU) or temozolomide resulted in synergistic killing. Synergistic killing was more often observed in cell lines retaining wild-type p53 activity (U87MG, LN-229) than in p53 mutant cell lines (LN-18, T98G, U373MG). Drug exposure resulted in enhanced TRAIL-R2 expression, but decreased TRAIL-R4 expression in U87MG cells. Ectopic expression of dominant-negative p53 V135A abrogated the druginduced changes in TRAIL-R2 and TRAIL-R4 expression, but had no eect on synergy. Thus, neither wildtype p53 function nor changes in TRAIL receptor expression were required for synergy. In contrast, synergy resulted possibly from drug-induced cytochrome c release from mitochondria, serving as an ampli®er of the TRAIL/Apo2L-mediated cascade of caspase activation. These data provide novel insights into the role of the TRAIL/Apo2L system in malignant gliomas and illustrate that TRAIL/Apo2L-based immunochemotherapy may be an eective therapeutic strategy for these lethal neoplasms. Oncogene (2001) 20, 4128 ± 4137.
Introduction
Death receptor targeting is an attractive approach of experimental treatment for solid tumors that are resistant to radiotherapy and chemotherapy, including malignant gliomas (Weller et al., 1998a) . Among the family of cytokines referred to as death ligands, TRAIL/Apo2L has attracted special interest for therapeutic purposes. This is because TRAIL/Apo2L seemed to be rather inactive against untransformed cells but readily induced apoptosis in various cancer cell lines (Wiley et al., 1995; Pitti et al., 1996) , including human malignant glioma cell lines (Rieger et al., 1998) . Moreover, TRAIL/Apo2L inhibited tumor growth without causing systemic toxicity in xenograft models of breast or colon cancer and glioma in nude mice Roth et al., 1999; Walczak et al., 1999; Nagane et al., 2000) . This selectivity of action against neoplastic cells may be related to the complex patterns of TRAIL/Apo2L receptor expression. TRAIL/Apo2L interacts with at least four cell surface receptors, two of which transmit a death signal (TRAIL-R1/DR4, TRAIL-R2/DR5) and two of which (TRAIL-R3/DcR1, TRAIL-R4/DcR2) do not (Ashkenazi and Dixit, 1998) . Preferential expression of agonistic receptors might confer high susceptibility to apoptosis whereas expression of TRAIL-R3 and TRAIL-R4 might be protective. Whether receptor expression patterns truly underlie the resistance of untransformed cells to TRAIL/Apo2L-induced apoptosis, remains to be investigated. Here, we characterize TRAIL-R expression and sensitivity to TRAIL/ Apo2L-induced apoptosis in a panel of human malignant glioma cell lines and study the molecular mechanisms underlying synergistic glioma cell killing by TRAIL/Apo2L and cancer chemotherapeutic drugs.
Results

Expression of TRAIL-R in human malignant glioma cell lines
The expression of TRAIL-R at the cell surface was assessed by¯ow cytometry. Representative pro®les are shown in Figure 1a . Quantitative data for TRAIL-R1, -R2, -R3 and -R4 are summarized in Figure 1b . All glioma cell lines expressed TRAIL-R2. The speci®c¯uorescence indexes (SFI) assumed values of more than 20, e.g., in A172 cells. In contrast, the SF1 for TRAIL-R1 did not exceed three. Only four cell lines (LN-18, LN-428, D247, LN-319) exhibited a distinct level of TRAIL-R1 expression. TRAIL-R3 reached a signi®cant level of expression in LN-428 only. TRAIL-R4 was more abundantly expressed, with four lines exhibiting a SFI of more than two. Note that the SFI values among the dierent receptors cannot be compared directly since the SFI is determined both by the level of expression and by the anity of the antibodies used. The TRAIL-R expression levels in the tumor cell lines were compared with those in the SV40-transformed non-neoplastic SV-FHAS astrocyte cell line. These cells expressed lower TRAIL-R2 levels than any of the neoplastic (glioma) cell lines, but detectable levels of both TRAIL-R3 and TRAIL-R4 (Figure 1b ).
Sensitivity to TRAIL/Apo2L-induced apoptosis
The sensitivity of the glioma cells to TRAIL/Apo2L-induced apoptosis was assessed in short-term (16 h) cytotoxicity assays. These experiments were performed in the absence or presence of CHX, an inhibitor of protein synthesis because inhibition of protein synthesis enhances glioma cell sensitivity to cytotoxic cytokines (Weller et al., 1994) . In the absence of CHX, eight of 12 cell lines exhibited EC 50 values above 2000 ng/ml and may thus be considered TRAIL/Apo2L-resistant (Table 1) . CHX greatly enhanced TRAIL/Apo2L-induced apoptosis in eight of 12 cell lines. CHX was dispensable for apoptosis in the highly sensitive LN-18 cell line, and CHX failed to promote apoptosis in U138MG, U373MG and LN-308 cells, and in the SV-FHAS astrocyte cell line. The latter three glioma cell lines (U138MG, U373MG, LN-308) are characterized by low TRAIL-R2 and absent TRAIL-R1 expression. The other two cell lines with low TRAIL-R2 expression, D247MG and LN-319, express signi®cant levels of TRAIL-R1, which appear to confer sensitivity to apoptosis. Statistical analysis revealed strong correlation between TRAIL-R2 expression and apoptosis in response to TRAIL/Apo2L at 2000 ng/ml in the absence of CHX (r=0.72, P=0.008). This correlation failed to achieve statistical signi®cance in the presence of CHX (r=0.56, P=0.06) . No correlation between the expression of TRAIL-R1, TRAIL-R3 or TRAIL-R4 and sensitivity to apoptosis became apparent. The glioma cells were co-treated with various concentrations of TRAIL/Apo2L and the drugs for 24 h. These experiments were performed with LN-229, U87MG, U373MG, T98G and LN-18 cells. Topotecan, CCNU, cisplatin, teniposide, vincristine, temozolomide and doxorubicin were studied in combination with TRAIL/Apo2L. Synergistic eects determined by isobologram analysis (Berenbaum, 1981) were observed for topotecan and CCNU in LN-229 and U87MG cells, for cisplatin in U87MG cells, for teniposide in LN-229 cells, for vincristine and temozolomide in LN-229, U87MG and T98G cells, and for doxorubicin in LN-229 and T98G cells. There was no synergy in LN-18 cells which are highly TRAIL/Apo2L-sensitive constitutively. Moreover, U373MG cells which are resistant to TRAIL/Apo2L (Table 1) were not sensitized to TRAIL/Apo2L by any drug. Representative isobologram analyses for TRAIL/Apo2L and topotecan, CCNU or temozolomide in U87MG cells are shown in Figure 2 .
Wild-type p53 activity or p53-mediated changes in TRAIL-R expression are not required for synergy Functional p53 activity in the 12 glioma cell lines has been previously studied (Weller et al., 1998b) and recently been con®rmed using a p53 reporter assay (Schmidt et al., 2001) . Coexposure to TRAIL/Apo2L and cytotoxic drugs resulted in more synergistic killing in cell lines retaining wild-type p53 activity (U87MG, LN-229) than in p53 mutant cell lines (LN-18, T98G, U373MG). We therefore next determined whether there is a causal relationship between p53 activity and synergy. U87MG and LN-229 cells were engineered to express murine mutant p53 V135A which has previously been characterized as a dominant-negative p53 mutant in human glioma cells (Figure 3a) . The dominant-negative activity of p53 V135A in U87MG and LN-229 cells was ascertained by the inhibition of camptothecin-induced p21 accumulation in cells engineered to express p53 The cells were exposed to TRAIL/Apo2L for 16 h in the absence or presence of CHX (10 mg/ml). Survival was assessed by crystal violet staining. Data are expressed as mean EC 50 values (n=3, s.e.m.510%) . We next assessed changes in TRAIL-R expression as a possible mechanism underlying synergy ( Figure  3c ). Exposure to CCNU enhanced TRAIL-R2 expression in both cell lines and decreased TRAIL-R4 expression in U87MG cells, consistent with a more apoptosis-sensitive phenotype. No such eect was seen in U373MG cells which are mutant for p53 (data not shown). The changes in TRAIL-R2 and TRAIL-R4 expression were p53-dependent since they were not observed in U87MG cells expressing dominant-negative p53 V135A ( Figure 3c ). However, expression of p53 V135A did not interfere with the synergistic killing by TRAIL/Apo2L and CCNU (Figure 3d) . Similarly, p53
V135A abrogated the CCNU-mediated increase in TRAIL-R2 expression, but did not aect synergistic killing mediated by CCNU and TRAIL, in LN-229 cells. Thus, neither functions of wild-type p53, that are blocked by dominant-negative p53 V135A , nor druginduced changes in TRAIL receptor expression are required for synergy.
Synergy of TRAIL/Apo2L and CCNU linked to mitochondrial cytochrome c release triggered by subtoxic concentrations of CCNU The molecular events during synergistic induction of apoptosis by TRAIL/Apo2L and cancer chemotherapeutic drugs were further characterized in U87MG cells co-treated with TRAIL/Apo2L and CCNU at approximate EC 15 concentrations. A prominent release of cytochrome c from mitochondria was induced by CCNU alone, but not by TRAIL/Apo2L alone ( Figure  4a ). Co-exposure to TRAIL/Apo2L and CCNU resulted in enhanced cytochrome c release compared with CCNU treatment alone. In contrast, CCNU alone failed to induce the processing of caspases 3, 7 or 9, whereas caspase cleavage was readily induced by TRAIL/Apo2L alone (Figure 4b ). The processing of caspases 9 and 3 was accelerated and more prominent in cells co-treated with TRAIL/Apo2L and CCNU than in cells treated with TRAIL/Apo2L alone. Note, for example, the reduction of procaspase levels at 4 h of co-treatment for all three caspases, or the more ecient processing to p35/caspase 9 or p17/caspase 3 in co-treated cells at 2 h. In contrast, no such eect was observed for caspase 7. Enhanced caspase activity triggered by co-treatment as opposed to single agent treatment became also apparent in an enzymatic uorimetric assay for DEVD-amc-cleaving caspase activity (Figure 4c ).
Caspase 8 processing is required for synergistic activity of TRAIL/Apo2L and CCNU
The role of TRAIL-R3 and TRAIL-R4 in TRAIL/ Apo2L signaling has remained obscure. We examined whether synergy of TRAIL/Apo2L and CCNU strictly depended on death signaling through TRAIL-R1 and TRAIL-R2. To test this, we generated U87MG cells expressing the viral preferential caspase 8 inhibitor, crm-A (Figure 5a ). As predicted from our previous studies with crm-A-transfected LN-18 and LN-229 cells (Glaser et al., 1999) , crm-A-transfected U87MG cells were protected from TRAIL/Apo2L-induced apoptosis but retained sensitivity to CCNU (Figure 5b,c) . Ectopic expression of crm-A also prevented any We also examined how bcl-2 aected the synergistic glioma cell killing induced by TRAIL/Apo2L and CCNU. Bcl-2-transfected U87MG cells (Figure 6a) showed unaltered sensitivity to CCNU in a 24 h acute exposure assay and moderate protection from TRAIL/Apo2L-induced apoptosis (data not shown). In contrast to mitochondrial cytochrome c release triggered by CD95L (Hermisson et al., 2000) , cytochrome c release induced by CCNU was unaected by bcl-2 (Figure 6b ). Bcl-2 had also no eect on the extent of synergy when U87MG cells were coexposed to TRAIL/Apo2L and CCNU (Figure 6c ), providing further circumstantial evidence for a role of cytochrome c release in the process of synergy.
Discussion
TRAIL/Apo2L-induced apoptosis is a novel experimental approach to the treatment of malignant glioma (Rieger et al., 1998) . Both local and systemic application of TRAIL/Apo2L result in the regression of U87MG xenograft gliomas in nude mice (Roth et al., 1999; Nagane et al., 2000) . Since all preclinical studies had indicated a striking lack of toxicity of TRAIL/Apo2L on normal cells Roth et al., 1999; Walczak et al., 1999; Nagane et al., 2000) , clinical trials had been discussed and expected with signi®cant hope for ecacy. A recent report on the induction of apoptosis by TRAIL/Apo2L in normal human hepatocytes cultured in vitro (Jo et al., 2000) has raised some concerns regarding the safety of systemic TRAIL/Apo2L administration in humans. However, these ®ndings await con®rmation, and it needs to be carefully examined under which in vitro and in vivo conditions non-neoplastic cells may acquire sensitivity to TRAIL/Apo2L.
Here we studied TRAIL-R expression in human malignant glioma cell lines (Figure 1 ). TRAIL-R2 was highly expressed, whereas TRAIL-R1 was expressed at signi®cant levels in only four of 12 cell lines. TRAIL-R3 and TRAIL-R4 were less frequently expressed. More than half of the glioma cell lines were rather resistant to TRAIL/Apo2L-induced apoptosis unless co-treated with an inhibitor of protein synthesis, CHX (Table 1) . Only three cell lines remained TRAIL/ Apo2L-resistant in the presence of CHX. The nonneoplastic astrocyte cell line, SV-FHAS, expressed little TRAIL-R2 and was resistant to TRAIL/Apo2L. Among the glioma cell lines, TRAIL-R2 expression was a good predictor of sensitivity to apoptosis. In contrast, expression of TRAIL-R3 or TRAIL-R4 was not associated with resistance to TRAIL/Apo2L-induced apoptosis.
A comparison of the data reported here (Table 1 ) and our previous data on the p53 status in the same cell lines revealed that cell lines retaining p53 function assessed by reporter assay or accumulation of p53 in response to genotoxic stress (Van Meir et al., 1994; Weller et al., 1998b; Schmidt et al., 2001) did not dier in their TRAIL/Apo2L sensitivity from p53 mutant cell lines. Similarly, although ectopic expression of bcl-2 or bcl-X L inhibited TRAIL/Apo2L-induced apoptosis in glioma cells (Rieger et al., 1998) , endogenous expression levels of bcl-2 family proteins, data as reported previously (Weller et al., 1998b) and con®rmed to be stable over time (data not shown), did not explain the dierential susceptibility to TRAIL/Apo2L-induced apoptosis in this panel of glioma cell lines.
There was strong synergistic glioma cell killing in response to the combination of TRAIL/Apo2L with various cancer chemotherapy drugs, including drugs which kill by diering modes of action, as previously reported for CD95L (Roth et al., 1997) . The role of p53 for the synergy of TRAIL/Apo2L and radiochemotherapy remains controversial. Numerous studies have con®rmed that genotoxic stress may increase TRAIL-R2 (DR5) expression in a p53-dependent manner (Sheikh et al., 1998) . Moreover, we report here that p53 mediates a reduction in the expression levels of the putatively antiapoptotic TRAIL-R4/DcR2 receptor in response to cytotoxic drugs (Figure 3) , an event also predicted to result in enhanced sensitivity to apoptosis. Similar to the present work on glioma cells and chemotherapy, breast cancer cells: (i) exhibited synergistic killing by TRAIL/Apo2L and irradiation; (ii) synergy was more prominent in p53 wild-type than in p53 mutant cells; and (iii) genotoxic stress (irradiation) enhanced TRAIL-R2 expression (Chinnaiyan et al., 2000) . However, in contrast to our data (Figure 3) , dominant-negative p53 abrogated the synergy of TRAIL/Apo2L and irradiation. Although the approach to determine synergy was not as rigorous as in our study, e.g., did not use isobologram analysis or at least compare isoeective concentrations of the single agents, these data indicate that the molecular mechanisms underlying synergy may be cell typespeci®c. The present study shows that both wild-type p53 activity inhibited by p53
V135A
, and drug-induced p53-mediated changes in TRAIL-R2 and TRAIL-R4 expression, are dispensable for the synergy of CCNU and TRAIL/Apo2L in glioma cells.
Preliminary evidence suggests that the synergy of TRAIL/Apo2L and CCNU involves the potentiation of the TRAIL/Apo2L-triggered cascade of caspase activation by a CCNU-induced, apparently caspaseindependent cytochrome c release from mitochondria ( Figure 4) . In principle, it is also possible that more ecient triggering of the caspase cascade by cotreatment upstream of mitochondria facilitated cytochrome c release as the mechanism underlying synergy. BID cleavage is unlikely to play a role here since death receptor-mediated apoptosis of glioma cells involves BID cleavage downstream, not upstream, of mitochondrial cytochrome c release (Glaser et al., 2001) . Future studies will address why the mitochondrial cytochrome c released by CCNU is not sucient to activate caspases on its own. In contrast to glioma cells, breast cancer cell lines were reported to exhibit signi®cant caspase activation when treated with those drugs that acted in synergy with TRAIL/Apo2L (Keane et al., 1999) . Importantly, bcl-2 gene transfer into the glioma cells inhibited CD95L-evoked cytochrome c release but did not interfere with drug-induced cytochrome c release or with the extent of synergy (Figure 6b,c) , corroborating the hypothesis that drug-induced cytochrome c release mediates synergy. Further, caspase 8 processing seems to be absolutely required for synergy since synergy and TRAIL/Apo2L-induced apoptosis were abrogated by crm-A ( Figure 5) .
The strong synergy of TRAIL/Apo2L and various cancer chemotherapy drugs reported here and by Nagane et al. (2000) corresponds to previous observations when chemotherapy was combined with CD95L in glioma cells (Roth et al., 1997) . Moreover, synergy of TRAIL/Apo2L and cisplatin has recently been extended to the in vivo U87MG xenograft model (Nagane et al., 2000) . We thus conclude that TRAIL/ Apo2L-based immunochemotherapy may be an eective strategy for the treatment of human malignant gliomas.
Materials and methods
Chemicals and cell lines
TRAIL/Apo2L was kindly provided by A Ashkenazi (San Francisco, CA, USA). Cytotoxic drugs were obtained from the indicated sources: teniposide, cisplatin (Bristol, Munich, Germany); topotecan (SmithKline Beecham, King of Prussia, PA, USA); puromycin, vincristine, doxorubicin (Sigma, Deisenhofen, Germany), CCNU (Medac, Hamburg, Germany), temozolomide (Schering Plough, Kenilworth, NJ, USA); hygromycin (Roche, Mannheim, Germany). Asp-Glu-Val-Asp-7-amido-4-methylcoumarine (DEVD-amc) was obtained from Bachem (Heidelberg, Germany). The mouse monoclonal anti-crm-A and anti-human cytochrome c antibodies were purchased from Pharmingen (San Diego, CA, USA), the mouse monoclonal antibody to human caspase 8 (C15) was prepared as described (Scadi et al., 1997) . Anti-human caspase 3 antibody (mouse monoclonal) was obtained from Transduction Laboratories (Lexington, KY, USA), antibodies to human caspases 7 and 9 were kindly provided by Dr Y Lazebnik (Cold Spring Harbor, NY, USA). PAb240 p53 and N19 bcl-2 antibodies were obtained from Santa Cruz (Santa Cruz, CA, USA). Antihuman TRAIL-R1 (M272), -R2 (M413), -R3 (M430) and -R4 (M444) antibodies were prepared as described . Anti-mouse IgG was purchased from Amersham (Braunschweig, Germany). The human malignant glioma cell lines, kindly provided by Dr N de Tribolet (Lausanne, Switzerland), were cultured in DMEM containing 10% fetal calf serum, glutamine (1 mM) and penicillin (100 IU/ml)/streptomycin (100 mg/ml) (Weller et al., 1998b V135A driven by the long terminal repeat promoter (Ryan et al., 1993) or control transfectants were cultured in complete medium supplemented with hygromycin (200 mg/ml). pEFr-FLAGpuro and pEFr-FLAG-puro/crm-A, obtained from A Strasser (Melbourne, Australia), were used to generate U87MG sublines expressing a puromycin resistance gene only or crm-A. These transfectants were cultured in complete medium supplemented with puromycin (4 mg/ml). The plasmids BMG-neo and BMG-neo/bcl-2, kindly provided by H Karasuyama (Basel, Switzerland) and E Podack (Miami, FL, USA), were used to generate U87MG-bcl-2 and a U87MG neomycin-resistant subline (neo), as described (Weller et al., 1995) . Pooled transfectants rather than a single clone of transfected cells were used to avoid artifacts from cloning.
Flow cytometry
The expression of TRAIL receptors TRAIL-R1, -R2, -R3 and -R4 was determined by¯ow cytometry using a Becton Dickinson FACScalibur cytometer and Cell Quest Software (Heidelberg, Germany). Brie¯y, 10 6 cells were washed with phosphate-buered saline (PBS) and detached from the culture¯ask by incubation with cell dissociation buer (Gibco ± BRL, Eggenstein, Germany) for 10 min at 378C, centrifuged, washed again and then incubated with 100 ml ow cytometry buer (1% bovine serum albumin, 0.01% sodium azide, in PBS) per sample containing 10% rabbit serum for 30 min at 48C. The cells were then centrifuged and incubated with the corresponding primary antibody (10 mg/ ml) or mouse IgG 1 isotype control antibody in 100 ml¯ow cytometry buer for 1 h at 48C. After two further washes in 2 ml¯ow cytometry buer, the cells were incubated with biotinylated secondary antibody (biotinylated rabbit antimouse f(ab) 2 ; Dakopatts, Glostrup, Denmark), diluted 1 : 200 in¯ow cytometry buer for 20 min at 48C, washed twice with 2 ml¯ow cytometry buer and incubated with 5 ml streptavidin-phycoerythrin (Sigma) in 100 ml buer for 20 min at 48C. After two ®nal washes, the cells were resuspended in 300 ml PBS containing 1% formaldehyde and measured within 24 h. A minimum of 10 4 cells were counted and the results were presented as histograms. The SF1 was calculated as the ratio of the geometric mean uorescence values obtained with the speci®c antibody versus isotype control antibody.
Immunoblot analysis
Glioma cells grown to subcon¯uency were washed with cold PBS, harvested into ice-cold PBS containing phenylmethylsulfonyl¯uoride (PMSF) (10 mg/ml) with a cell scraper, lysed in lysis buer containing 50 mM TRISHCl, pH 8, 120 mM NaCl, 0.5% NP-40, 100 mg/ml PMSF, 10 mg/ml leupeptin and 2 mg/ml aprotinin, for 15 min on ice and centrifuged at 13 000 r.p.m. for 10 min at 48C. The protein concentration was determined by the Bio-Rad Protein Assay (Bio-Rad, Munich, Germany). Soluble proteins (20 mg per lane) were separated by SDS ± PAGE and blotted to nitrocellulose by standard procedures. Equal loading was ascertained by Ponceau S staining and by bactin immunodetection. The membranes were pretreated for 2 h with PBS containing 5% skim milk, 0.05% Tween 20 and then incubated for 16 h at 48C with the corresponding primary antibody, washed and then incubated with horseradish peroxidase-coupled secondary antibody (1 : 3000) for 1 h at room temperature. Visualization of protein bands was accomplished using ECL. Cytoplasmic protein lysates for the assessment of cytochrome c release from mitochondria were obtained as described (Hermisson et al., 2000) .
DEVD-amc-cleaving caspase activity assay
The cells were seeded on 96-well plates (10 4 per well), adhered for 24 h, treated as indicated and lysed in lysis buer (60 mM NaCl, 5 mM TRIS-HCl, 2.5 mM EDTA, 0.25% NP-40) for 10 min. Then the¯uorogenic substrate, DEVD-amc, was added to a ®nal concentration of 12.5 mM. Fluorescence was measured every 10 min at 360 nm excitation and 480 nm emission wavelengths using a CytoFluor 2300 cyto¯uori-meter.
Viability assay
The cells were seeded at 10 4 cells per well in 96-well plates, allowed to attach for 24 h and then exposed to cytotoxic drugs or TRAIL/Apo2L or both in serum-free medium. Survival was determined by staining with 0.5% crystal violet in 20% methanol for 20 min at room temperature. The plates were washed extensively under running tap water and airdried. The staining was dissolved in sodium citrate (0.1 M in 100% ethanol). Optical density values were measured in an ELISA reader at 550 nm wavelength.
Statistical analysis and determination of synergy
Data are representative of mean values and s.e.m. of experiments performed at least three times with similar results. Synergy of TRAIL/Apo2L and cytotoxic drugs was evaluated by the fractional product method (Figures 3d, 5d and 6c), as in previous studies (Roth et al., 1997) or by the isobologram method (Berenbaum, 1981) (Figure 2) . For the latter, the cells were treated with dierent concentrations of each agent (TRAIL or cytotoxic drug) alone or with the two agents in combination. The relative survival was assessed and the EC 50 values (median eect dosis) for each drug administered alone, or in combination with a ®xed concentration of the second agent, were established from the concentration-eect curves. The EC 50 values of co-treatment were divided by the EC 50 value of each drug in the absence of the other drug. In a graphical presentation, the straight line connecting the EC 50 values of the two agents when applied alone corresponds to additivity, or independent eects of both agents. Values below this line indicate synergy, values above this line indicate antagonism. A possible relationship between death receptor expression and sensitivity to death ligandinduced apoptosis was assessed by multiple linear correlation analysis. For these analyses, SFI values were used to assess death receptor expression, and survival values at 2000 ng/ml TRAIL/Apo2L were used to assess sensitivity to apoptosis because EC 50 values were not achieved under all conditions.
